As a GHRH analogue, Mod GRF 1-29 (CJC-1295 without DAC) acts on receptors at the pituitary gland to stimulate the release of Human Growth Hormone. Mod GRF 1-29 acts upon receptors located in the anterior pituitary gland, and signals the pituitary gland to increase Human Growth Hormone production and cause a release of massive quantities of Human Growth Hormone in a pulsatile manner.
The effects of Mod GRF 1-29 are very similar from what would be expected from synthetic HGH administration over the long term (see the Human Growth Hormone profile here), although the amount of time that the released human growth hormone will remain in circulation is of a far less amount of time than synthetic Human Growth Hormone does. Therefore, multiple applications of Mod GRF 1-29 is recommended throughout the day in order to simulate Human Growth Hormone levels that remain high on a constant basis.
Mod GRF 1-29 (CJC-1295 without DAC) is commonly combined with a Ghrelin mimetic (also known as a GHRP – Growth Hormone Releasing Hexapeptide), such as GHRP-6, GHRP-2, Hexarelin, or Ipamorelin in order to initiate and amplify a greater pulse of HGH from the pituitary compared to Mod GRF 1-29 used solitarily on its own. The effects of a GHRH analogue (such as Mod GRF 1-29) and a Ghrelin mimetic (a GHRP such as GHRP-6 or Ipamorelin) are synergistic and amplify the release of HGH.
For research purposes only.